LEIDEN, NETHERLANDS -- (MARKET WIRE) -- September 07, 2006 -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a STAR™ licensing agreement with UCB (Euronext: UCB), a leading biopharmaceutical company with headquarters in Brussels, making UCB the first European STAR™ licensee. The agreement covers a 5-year non-exclusive STAR™ research license for the production of monoclonal antibodies.
